iRGD-NaGd(MoO 4 ) 2 : A Tumor-Targeted Magnetic Resonance Contrast Agent Activating Immunotherapy via the cGAS-STING Pathway
ACS Applied Materials & Interfaces · 2025
DOI: 10.1021/acsami.5c03469 ↗At a glance
Journal article in ACS Applied Materials & Interfaces, 2025. Written by Ling Yu and 17 co-authors. Institution: Zhejiang Key Laboratory of Imaging and Interventional Medicine, Zhejiang Engineering Research Center of Interventional Medicine Engineering and Biote…. Major MEDLINE topics: Immunotherapy, Contrast Media, Membrane Proteins, Nucleotidyltransferases. Cited 4 times so far (Crossref); 53 references. Funded by: Science and Technology Department of Zhejiang Province, National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.
Abstract (original language)
Because of the high incidence and mortality of cancer, there is an urgent need for more effective tumor diagnostic imaging and treatment strategies. Single-molecule therapeutics have emerged as a promising strategy to address the limitations of independent imaging and therapeutic modalities, thereby significantly reducing adverse side effects for patients. For the first time, we successfully synthesized NaGd(MoO4)2 nanoparticles via a homogeneous precipitation method in polyol media, which serve as a single-molecule agent for MRI imaging and metallic immunotherapy. With the addition of iRGD, we obtained iRGD-NaGd(MoO4)2. The iRGD-NaGd(MoO4)2 nanoparticles exhibit excellent tumor-targeting capability and significantly enhance T1-weighted MRI contrast with a longitudinal relaxivity of 4.95 mM-1 s-1. In terms of antitumor immunotherapy, iRGD-NaGd(MoO4)2 not only directly activates the cGAS-STING pathway but also induces ferroptosis in tumor cells, resulting in the generation of aberrant dsDNA and thereby indirectly activating the STING pathway. The dual pathway elicits a tumor-specific immune response, plays a significant role in promoting the maturation of DC cells, activates DC and T cells to secrete high levels of TNF-α, IL-6 and other cytokines, and regulates the polarization of macrophages from M2 phenotype to M1 phenotype. This mechanism significantly suppresses tumor growth. Beyond the metallic immunotherapy induced by Mn2+, Zn2+, and Co2+, this study provides robust validation of MoO42- as an effective cGAS-STING agonist. Moreover, this study achieved the synergy of multiple disciplines including biomaterials, tumor immunotherapy and medical imaging. This not only promotes the innovative integration in various fields, but also provides new treatment strategies and imaging tools for cancer treatment, which has important clinical application prospects.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Zhejiang Key Laboratory of Imaging and Interventional Medicine, Zhejiang Engineering Research Center of Interventional Medicine Engineering and Biotechnology, The Fifth Affiliated Hospital of Wenzhou Medical University,…
- Department of Radiology, Lishui Central Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.
- Clinical College of the Affiliated Central Hospital, School of Medicine, Lishui University, Lishui 323000, China.
- Key Laboratory of Precision Medicine of Lishui, Lishui Central Hospital, Lishui 323000, China.
ORCID profiles: Jiansong Ji
Funding
- Science and Technology Department of Zhejiang Province
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
- Lishui Innovation Consortium-Key Research and development Program Projects
- Zhejiang Medicine and Health science and Technology Project
Cite
APA
Yu, L., Qiu, F., Hu, Y., Liao, T., Zhai, M., Wu, R., He, Q., Hu, H., Xia, S., Hui, J., Wang, Z., Yang, Y., Qiu, R., Chen, M., Chen, W., Tu, J., Ji, J., & Lu, C. (2025). iRGD-NaGd(MoO 4 ) 2 : A Tumor-Targeted Magnetic Resonance Contrast Agent Activating Immunotherapy via the cGAS-STING Pathway. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.5c03469
Vancouver
Yu L, Qiu F, Hu Y, Liao T, Zhai M, Wu R, et al. iRGD-NaGd(MoO 4 ) 2 : A Tumor-Targeted Magnetic Resonance Contrast Agent Activating Immunotherapy via the cGAS-STING Pathway. ACS Applied Materials & Interfaces. 2025. doi:10.1021/acsami.5c03469
BibTeX
@article{Yu2025,
author = {Yu, Ling and Qiu, Fengkai and Hu, Yumin and Liao, Tingting and Zhai, Mengqian and Wu, Ronghua and He, Qianhui and Hu, Huilin and Xia, Shuiwei and Hui, Junguo and Wang, Zufei and Yang, Yang and Qiu, Rongfang and Chen, Minjiang and Chen, Weiqian and Tu, Jianfei and Ji, Jiansong and Lu, Chenying},
title = {iRGD-NaGd(MoO 4 ) 2 : A Tumor-Targeted Magnetic Resonance Contrast Agent Activating Immunotherapy via the cGAS-STING Pathway},
journal = {ACS Applied Materials & Interfaces},
year = {2025},
doi = {10.1021/acsami.5c03469}
}
EUVIMED